 Voytek Slowik
Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 5 | 2023 | 43 | 2.700 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2023 | 20 | 2.570 |
Why?
| | Hypertension, Portal | 2 | 2022 | 7 | 1.540 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2022 | 15 | 1.110 |
Why?
| | Child | 12 | 2023 | 3146 | 1.060 |
Why?
| | Endoscopy, Gastrointestinal | 2 | 2022 | 17 | 1.040 |
Why?
| | Esophageal and Gastric Varices | 2 | 2021 | 2 | 1.020 |
Why?
| | Humans | 17 | 2023 | 6599 | 0.970 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2023 | 11 | 0.850 |
Why?
| | Varicose Veins | 1 | 2021 | 1 | 0.840 |
Why?
| | Graft Rejection | 2 | 2020 | 31 | 0.810 |
Why?
| | Patient Participation | 1 | 2020 | 21 | 0.780 |
Why?
| | Sildenafil Citrate | 1 | 2020 | 1 | 0.770 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 1 | 0.770 |
Why?
| | Vasodilator Agents | 1 | 2020 | 3 | 0.770 |
Why?
| | Vascular Malformations | 1 | 2020 | 2 | 0.770 |
Why?
| | Healthcare Disparities | 1 | 2020 | 20 | 0.770 |
Why?
| | Weight Reduction Programs | 1 | 2020 | 24 | 0.760 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 37 | 0.750 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 82 | 0.720 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2019 | 1 | 0.700 |
Why?
| | Postoperative Complications | 1 | 2020 | 177 | 0.690 |
Why?
| | Pediatric Obesity | 1 | 2020 | 127 | 0.640 |
Why?
| | Leukocytes | 1 | 2017 | 3 | 0.620 |
Why?
| | Fibromatosis, Aggressive | 1 | 2015 | 3 | 0.540 |
Why?
| | Genes, APC | 1 | 2015 | 3 | 0.540 |
Why?
| | Adolescent | 6 | 2022 | 2087 | 0.540 |
Why?
| | Mutation | 2 | 2015 | 194 | 0.530 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2015 | 24 | 0.530 |
Why?
| | Male | 8 | 2022 | 3197 | 0.520 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 61 | 0.520 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 215 | 0.480 |
Why?
| | Child, Preschool | 5 | 2020 | 1459 | 0.450 |
Why?
| | Liver | 2 | 2023 | 119 | 0.420 |
Why?
| | Female | 7 | 2022 | 3436 | 0.400 |
Why?
| | Body Mass Index | 2 | 2022 | 155 | 0.390 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 317 | 0.380 |
Why?
| | Biomarkers | 2 | 2023 | 120 | 0.380 |
Why?
| | Portal Vein | 2 | 2020 | 8 | 0.370 |
Why?
| | Genetic Diseases, Inborn | 2 | 2019 | 18 | 0.300 |
Why?
| | Retrospective Studies | 2 | 2022 | 1251 | 0.270 |
Why?
| | Chemotactic Factors | 1 | 2023 | 1 | 0.240 |
Why?
| | Adult | 3 | 2023 | 1233 | 0.240 |
Why?
| | Biopsy | 1 | 2023 | 56 | 0.230 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 38 | 0.230 |
Why?
| | Ambulatory Care | 1 | 2023 | 46 | 0.230 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 4 | 0.220 |
Why?
| | Alanine Transaminase | 1 | 2022 | 5 | 0.220 |
Why?
| | Bilirubin | 1 | 2022 | 25 | 0.220 |
Why?
| | Secondary Prevention | 1 | 2022 | 7 | 0.210 |
Why?
| | Qa-SNARE Proteins | 1 | 2021 | 2 | 0.210 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2021 | 3 | 0.210 |
Why?
| | Immune System Diseases | 1 | 2021 | 6 | 0.210 |
Why?
| | Endoscopy | 1 | 2021 | 15 | 0.210 |
Why?
| | Urban Population | 1 | 2022 | 36 | 0.210 |
Why?
| | Rural Population | 1 | 2022 | 38 | 0.210 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 40 | 0.200 |
Why?
| | Liver Diseases | 1 | 2021 | 17 | 0.200 |
Why?
| | Infant, Newborn | 2 | 2021 | 790 | 0.200 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 1 | 0.200 |
Why?
| | Induction Chemotherapy | 1 | 2020 | 4 | 0.190 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 38 | 0.190 |
Why?
| | Fatigue | 1 | 2020 | 13 | 0.190 |
Why?
| | Health Care Surveys | 1 | 2020 | 32 | 0.190 |
Why?
| | Cryptosporidiosis | 1 | 2020 | 3 | 0.190 |
Why?
| | Immunocompromised Host | 1 | 2020 | 7 | 0.190 |
Why?
| | Societies, Medical | 1 | 2020 | 43 | 0.190 |
Why?
| | Postoperative Care | 1 | 2020 | 28 | 0.190 |
Why?
| | Quality Improvement | 1 | 2020 | 60 | 0.190 |
Why?
| | Follow-Up Studies | 1 | 2020 | 315 | 0.180 |
Why?
| | Hepatic Encephalopathy | 1 | 2019 | 1 | 0.180 |
Why?
| | Ascites | 1 | 2019 | 4 | 0.180 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 9 | 0.180 |
Why?
| | Prospective Studies | 1 | 2020 | 508 | 0.170 |
Why?
| | Treatment Outcome | 1 | 2020 | 624 | 0.160 |
Why?
| | United States | 1 | 2020 | 646 | 0.160 |
Why?
| | Infant | 2 | 2020 | 1396 | 0.160 |
Why?
| | Amyloidosis | 1 | 2017 | 1 | 0.150 |
Why?
| | Liver Regeneration | 1 | 2017 | 1 | 0.150 |
Why?
| | Osteoarthritis | 1 | 2017 | 2 | 0.150 |
Why?
| | Immune System | 1 | 2017 | 4 | 0.150 |
Why?
| | Cell Cycle | 1 | 2017 | 14 | 0.150 |
Why?
| | Disease Models, Animal | 1 | 2017 | 55 | 0.150 |
Why?
| | Sepsis | 1 | 2017 | 22 | 0.150 |
Why?
| | Pediatrics | 1 | 2019 | 170 | 0.150 |
Why?
| | Mice | 1 | 2017 | 290 | 0.140 |
Why?
| | Animals | 1 | 2017 | 563 | 0.130 |
Why?
| | Neoplasms | 1 | 2017 | 119 | 0.130 |
Why?
| | Lymphoproliferative Disorders | 1 | 2014 | 4 | 0.130 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 7 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 11 | 0.130 |
Why?
| | Pelvic Bones | 2 | 2010 | 8 | 0.120 |
Why?
| | Fractures, Bone | 2 | 2010 | 35 | 0.120 |
Why?
| | Ligaments | 1 | 2010 | 4 | 0.100 |
Why?
| | Models, Biological | 1 | 2010 | 46 | 0.100 |
Why?
| | Ligaments, Articular | 1 | 2009 | 1 | 0.090 |
Why?
| | Age of Onset | 1 | 2021 | 27 | 0.050 |
Why?
| | RNA, Viral | 1 | 2021 | 16 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 16 | 0.050 |
Why?
| | Registries | 1 | 2021 | 85 | 0.050 |
Why?
| | Biliary Tract Diseases | 1 | 2020 | 4 | 0.050 |
Why?
| | Diarrhea | 1 | 2020 | 18 | 0.050 |
Why?
| | Genetic Variation | 1 | 2021 | 161 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 6 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2014 | 7 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 6 | 0.030 |
Why?
| | Phosphorylation | 1 | 2014 | 21 | 0.030 |
Why?
| | Finite Element Analysis | 1 | 2010 | 1 | 0.020 |
Why?
| | Computer Simulation | 1 | 2010 | 22 | 0.020 |
Why?
| | Spine | 1 | 2009 | 3 | 0.020 |
Why?
| | Models, Anatomic | 1 | 2009 | 2 | 0.020 |
Why?
| | Cadaver | 1 | 2009 | 18 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2009 | 13 | 0.020 |
Why?
| | User-Computer Interface | 1 | 2009 | 10 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 11 | 0.020 |
Why?
| | Software | 1 | 2009 | 24 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2009 | 150 | 0.020 |
Why?
| | Aged | 1 | 2009 | 375 | 0.020 |
Why?
| | Middle Aged | 1 | 2009 | 648 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|